Search International and National Patent Collections

1. (WO2018177516) CANNABIDIOL DERIVATIVES AS INHIBITORS OF THE HIF PROLYL HYDROXYLASES ACTIVITY

Pub. No.:    WO/2018/177516    International Application No.:    PCT/EP2017/057389
Publication Date: Fri Oct 05 01:59:59 CEST 2018 International Filing Date: Thu Mar 30 01:59:59 CEST 2017
IPC: A61K 31/133
A61K 31/135
Applicants: EMERALD HEALTH PHARMACEUTICALS, INC.
Inventors: MUÑOZ BLANCO, Eduardo
NAVARRETE RUEDA, Carmen María
CRUZ TENO, Cristina
BELLIDO CABELLO DE ALBA, María Luz
Title: CANNABIDIOL DERIVATIVES AS INHIBITORS OF THE HIF PROLYL HYDROXYLASES ACTIVITY
Abstract:
Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF- 1α and HIF-2α levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types 10 and induce collagen contraction. Said cannabidiol quinol derivatives of Fomula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia–reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.